Geode Capital Management LLC Buys 85,234 Shares of BioVie Inc. (NASDAQ:BIVI)

Geode Capital Management LLC raised its stake in shares of BioVie Inc. (NASDAQ:BIVI) by 223.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 123,408 shares of the company’s stock after purchasing an additional 85,234 shares during the period. Geode Capital Management LLC owned 0.69% of BioVie worth $247,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Prosperity Wealth Management Inc. purchased a new stake in BioVie in the 4th quarter worth approximately $63,000. Sanders Morris Harris LLC bought a new position in shares of BioVie in the fourth quarter worth approximately $85,000. Finally, Drive Wealth Management LLC purchased a new stake in shares of BioVie in the fourth quarter worth $120,000. Hedge funds and other institutional investors own 4.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Brookline Capital Management raised shares of BioVie to a “strong-buy” rating in a report on Tuesday, March 18th.

BioVie Trading Up 40.4 %

NASDAQ:BIVI opened at $1.21 on Friday. The stock has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.88. BioVie Inc. has a 12-month low of $0.62 and a 12-month high of $7.50. The stock has a market capitalization of $22.33 million, a P/E ratio of -0.12 and a beta of 0.64.

BioVie (NASDAQ:BIVI) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.46) earnings per share (EPS) for the quarter.

BioVie Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.